Drug intelligence / Profile preview

CP4071

Development stage: Unknown
Lead developer: Signature BioScience
Modality: Small Molecules

Overview

CP4071 is a small molecule drug developed for the treatment of locally advanced or metastatic soft tissue sarcoma and other advanced sarcomas. It has also been investigated for ovarian cancer. The drug was evaluated in phase 2 clinical trials, primarily sponsored by Signature BioScience and the National Cancer Institute. Its mechanism of action and molecular targets have not been publicly disclosed in available sources. The primary indication is neoplasms, specifically soft tissue sarcoma[1][3].

Beyond the preview

Go deeper on CP4071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP4071.

Explore the full profile